This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Vieitez, P. Articles by Molina-Holgado, E. Search for Related Content PubMed PubMed Citation Articles by Vieitez, P. Articles by Molina-Holgado, E. Social Bookmarking                         What's this?

Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy

Endocrinology Department. Ramon y Cajal Hospital, Madrid, Spain, vieitezp{at}yahoo.com

Oscar Gómez

Laboratory of Neuroinflammation, Experimental Neurology Department, Paraplegic National Hospital, Toledo, Spain, ogomezt{at}sescam.jccm.es

Esther R Uceda

Life Science Division, NASA Ames Research Centre, Moffet Field, CA, USA

María Eugenia Vera

Endocrinology Department. Ramon y Cajal Hospital, Madrid, Spain

Eduardo Molina-Holgado

Laboratory of Neuroinflammation, Experimental Neurology Department, Paraplegic National Hospital, Toledo, Spain

Introduction. Our objective was to evaluate the effect of blocking the renin-angiotensin system (RAS) on the expression of transforming growth factor-beta 1 (TGF-β1), platelet derived growth factor-B (PDGF-B), tumour necrosis factor-alpha (TNF-) and vascular endothelial growth factor (VEGF) in diabetic kidney glomeruli.

Materials and Method. 1) Uninephrectomised streptozotocin induced diabetic rats were treated during eight months with vehicle (CD) or irbesartan (ID). Uninephrectomised non-diabetic rats were used as control group (ND). Protein urinary excretion and morphological renal damage were analysed. Glomerular expression of TGF-β1, PDGF-B, VEGF and TNF- were evaluated by Western blot and Immunohistochemistry. 2) Isolated glomeruli of diabetic rats were incubated 24-hours in the presence of different doses of irbesartan. Glomerular expression of TGF-β1, PDGF-B,TNF- and VEGF were determined by Western blot.

Results. ND and ID presented lower renal injury and proteinuria than CD (p<0.05). Glomerular expression of TGF-β1, PDGF-B,TNF- and VEGF were similar in ND and ID, but lower than in CD (p<0.05). In addition, in isolated diabetic rat glomeruli, irbesartan reduced the content of all these factors.

Conclusion. Systemic and local administration of irbesartan lowers glomerular expression of TGF-β1, PDGF-B, VEGF and TNF-.These data suggest that part of the effect of lowering the expression of these growth factors and cytokines is due to a direct blockade of glomerular RAS.

Key Words: angiotensin receptor blockers • diabetic nephropathy • glomeruli • growth factors • renin-angiotensin system

References

• Ioannou GN, Bryson CL, Boyko EJ Prevalence and trends of insulin resistance, impaired fasting glucose and diabetes. J Diabetes Complications 2007;21:363-70.[Medline] [Order article via Infotrieve]
• Marshall SM Recent advances in diabetic nephropathy. Clin Med 2004;4:277-82.[Web of Science][Medline] [Order article via Infotrieve]
• Steffes MW, Bilous RW, Sutherland DE et al. Cell and matrix components of the glomerular mesangium in type I diabetes. Diabetes 1992;41:679-84.[Abstract]
• Ichinose K., Kawasaki E., Eguchi K. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol 2007;27:554-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Weir MR Effects of renin-angiotensin system inhibition end-organ protection: can we do better? Clin Ther 2007;29:1803-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Karalliedde J., Viberti G. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 2006;20:239-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lee EY, Shim MS, Kim MJ et al. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Exp Mol Med 2004;36:65-70.[Web of Science][Medline] [Order article via Infotrieve]
• Kang YS, Park YG, Kim BK et al. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J Mol Endocrinol 2006;36:377-88.[Abstract/Free Full Text]
• Pimentel JL Jr, Sundell CL, Wang S. et al. Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy. Kidney Int 1995;48:1233-46.[Web of Science][Medline] [Order article via Infotrieve]
• Kagami S., Border WA, Miller DE et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-7.[Web of Science][Medline] [Order article via Infotrieve]
• Ziyadeh FN Mediators of diabetic renal disease: the case of TGF-β as the major mediator. J Am Soc Nephrol 2004;15(suppl 1):S55-S57.[Abstract/Free Full Text]
• Reeves WB, Andreoli TE Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 2000;97:7667-9.[Free Full Text]
• Fraser D., Wakefield L., Phillips A. Independent regulation of transforming growth factor beta 1 transcription and translation by glucose and platelet derived growth factor. Am J Pathol 2002;161:1039-49.[Abstract/Free Full Text]
• Yamabe H., Osawa H., Kaizuka M. et al. Platelet derived growth factor, basic fibroblast growth factor, and interferon gamma increase type IV collagen production in human fetal mesangial cells via a transforming growth factor beta dependent mechanism. Nephrol Dial Transplant 2000; 15:872-6.[Abstract/Free Full Text]
• Kalantarinia K., Awad AS, Siragy HM Urinary and renal interstitial concentrations of TNF- increase prior to the rise in albuminuria in diabetic rats. Kidney Int 2003;64:1208-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cooper ME, Vranes D., Youssef S. et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-R in experimental diabetes. Diabetes 1999;48:2229-39.[Abstract]
• Siragy HM, Awad A., Abadir P. et al. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor- in diabetic rats. Endocrinology 2003; 144:2229-33.[Abstract/Free Full Text]
• Cohen MP, Chen S., Ziyadeh FN et al. Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria and diabetic nephropathy. Kidney International 2005;68:1554-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Flyvbjerg A., Mogensen CE, Osterby R. et al. Renal hypertrophy in experimental diabetes. J Diabet Complications 1991;5:62-4.[CrossRef][Medline] [Order article via Infotrieve]
• Seyer-Hansen K. Renal hypertrophy in Streptozotocin diabetic rats. Clin Sci Mol Med 1976;51:551-5.[Web of Science]
• Bradford MM A rapid and sensitive method for the quantification of microgram quantities of protein utilising the principle of protein dye binding. Anal Biochem 1976;72:248-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Karl J., Burns G., Engel WD Development and standardisation of a new immunoturbidimetric HbA1C assay. Clin Lab 1993;39:991-6.
• Schlondorff D., Roczniak S., Satriano JA et al. Prostaglandin synthesis by isolated rat glomeruli: effect of angiotensin II. Am J Physiol 1980;239:F486-F495.[Web of Science][Medline] [Order article via Infotrieve]
• González-Albarrán O., Gómez O., Ruiz E. et al. Role of systolic blood pressures on the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity and hypertension (Zucker rats). Am J Hypertens 2003;16:979-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rossing P., Parving HH, Zeeuw D. Renoprotection by blocking the RAAS in diabetic nephropathy -fact or fiction? Nephron Dial Transplant 2006;21:2354-7.[CrossRef]
• Lewis EJ, Hunsicker LG, Clarke WR et al. Collaborative Study Group: Renoprotective effect ofthe angiotensinreceptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
• Kasiske BL, Kalil RS, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 1993;118:129-38.[Abstract/Free Full Text]
• Timmermans PB, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.[Web of Science][Medline] [Order article via Infotrieve]
• Matsusaka T., Hymes J., Ichikawa I. Angiotensin in progressive renal disease: Theory and practice. J Am Soc Nephrol 1996;7:2025-43.[Abstract]
• Wolf G., Neilson EG Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993;3:1531-40.[Abstract]
• Gross ML, El-Shakmak A., Szabo A. et al. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003;46:856-68.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Allard J., Buléon M., Cellier E. et al. ACE Inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular reception activation in diabetic rats. Am J Physiol Renal Physiol 2007;293:F1083-F1092.[Abstract/Free Full Text]
• Kitamura M., Ishikawa Y., Konta T. Explanted glomeruli: Utility and limitations. Exp Nephrol 2001;9:349-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.[Abstract/Free Full Text]
• Adamis AP, Miller JW, Bernal MT et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-50.[Web of Science][Medline] [Order article via Infotrieve]
• Marshall SM The podocyte: a potential therapeutic target in diabetic nephropathy? Curr Pharm Des 2007;13:2713-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Liu E., Morimoto M., Kitajima S. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007;18:2094-104.[Abstract/Free Full Text]
• Navarro JF, Milena FJ, Mora C. et al. Tumor necrosis factor- gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int 2005;68(suppl 99): S98-S102.[CrossRef]
• Sugimoto H., Shikata K., Wada J. et al. Advanced glycation end products cytokine nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumor necrosis factor- and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 1999;42:878-86.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fukui M., Nakamura T., Ebihara I. et al. Effects of enalapril on endothelin 1 and growth factor gene expression in diabetic rat glomeruli. J Lab Clin Med 1994;123:763-8.[Web of Science][Medline] [Order article via Infotrieve]
• Muller DN, Shagdarsuren E., Park JK et al. Immunosuppressive treatment protects against angiotensin II induced renal damage. Am J Pathol 2002;161:1679-93.[Abstract/Free Full Text]
• Chu SC, Tsai CH, Yang SF et al. Induction of vascular endothelial growth factor gene expression by proinflammatory cytokines in human pulp and gingival fibroblasts. J Endod 2004;30:704-07.[Web of Science][Medline] [Order article via Infotrieve]
• Ryuto M., Ono M., Izumi H. et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996;271:28220-8.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 9, No. 2, 96-102 (2008)
DOI: 10.3317/jraas.2008.018


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Vieitez, P. Articles by Molina-Holgado, E. Search for Related Content PubMed PubMed Citation Articles by Vieitez, P. Articles by Molina-Holgado, E. Social Bookmarking                         What's this?